Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10501789 | 0.83 | METAP2 (0.71) | METAP2 | |
| SCHEMBL10501634 | 0.83 | METAP2 (0.67) | METAP2 | |
| SCHEMBL10501611 | 0.82 | METAP2 (0.66) | METAP2 | |
| SCHEMBL10502440 | 0.80 | MPI (0.74) | METAP2 | |
| SCHEMBL10502578 | 0.77 | METAP2 (0.64) | METAP2 | |
| SCHEMBL10501773 | 0.76 | METAP2 (0.70) | METAP2 | |
| SCHEMBL10501917 | 0.75 | METAP2 (0.68) | METAP2 | |
| SCHEMBL1351720 | 0.75 | METAP2 (0.74) | METAP2 | |
| SCHEMBL10502450 | 0.74 | METAP2 (0.64) | METAP2 | |
| SCHEMBL10501727 | 0.74 | METAP2 (1.00) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172829-B2 | Use of small molecules for the treatment of clostridium difficile toxicity | SLC10A2, TCERG1, SBDS | METAP2 1571/4885 |
| US-20190142801-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | METAP2 1571/4885 |
| US-20170128420-A1 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | SLC10A2, TCERG1, SBDS | METAP2 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.